Login to Your Account

Immunicum Shares Rise on Cancer Vaccine Progress

By Cormac Sheridan
Staff Writer

Monday, August 19, 2013

Shares in Immunicum AB surged more than 40 percent Monday on promising signals from a Phase I/II trial of its kidney cancer vaccine, Intuvax. The optimism is based on preliminary data from a very small-scale study. The open-label trial recruited just 12 patients with metastatic renal cancer.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription